عرض مصدر تيجاسيرود

{{لا مصدر|تاريخ =مايو 2024}}
{{معلومات دواء
| English = Tegaserod
| Verifiedfields = changed
| verifiedrevid = 470478621
| IUPAC_name = (2''E'')-2-[(5-Methoxy-1''H''-indol-3-yl)methylene]-''N''-pentylhydrazinecarboximidamide
| image = Tegaserod structure.svg
| width = 143px
<!--Clinical data-->
| tradename =
| Drugs.com = {{drugs.com|monograph|tegaserod-maleate}}
| pregnancy_AU = B3
| pregnancy_US = B
| legal_status = Withdrawn
| routes_of_administration = Oral
<!--Pharmacokinetic data-->
| bioavailability = 10%
| protein_bound = 98%
| metabolism = [[معدة|Gastric]] and [[كبد|hepatic]]
| elimination_half-life = 11 ± 5 hours
| excretion = Fecal and [[كلية (توضيح)|renal]]
<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 189188-57-6
| ATC_prefix = A06
| ATC_suffix = AX06
| PubChem = 5362436
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01079
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 10609889
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 458VC51857
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02730
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 76370
<!--Chemical data-->
| C=16 | H=23 | N=5 | O=1
| molecular_weight = 301.39 g/mol
| smiles = CCCCCNC(=N)N\N=C\c2cnc1ccc(cc12)OC
| InChI = 1/C16H23N5O/c1-3-4-5-8-18-16(17)21-20-11-12-10-19-15-7-6-13(22-2)9-14(12)15/h6-7,9-11,19H,3-5,8H2,1-2H3,(H3,17,18,21)/b20-11+
| InChIKey = IKBKZGMPCYNSLU-RGVLZGJSBI
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C16H23N5O/c1-3-4-5-8-18-16(17)21-20-11-12-10-19-15-7-6-13(22-2)9-14(12)15/h6-7,9-11,19H,3-5,8H2,1-2H3,(H3,17,18,21)/b20-11+
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = IKBKZGMPCYNSLU-RGVLZGJSSA-N
}}
'''تيجاسيرود''' أو تيغاسيرود {{إنج|Tegaserod}} هو ناهض 5-HT4 مصنع من قبل شركة Novartis ويباع تحت اسم Zelnorm وZelmac ويستخدم لعلاج [[متلازمة القولون المتهيج|متلازمة القولون العصبي]] و[[إمساك (داء)|الإمساك]].